27 completed, 19 recruiting, 8 not yet recruiting, 7 terminated. 65 Phase 3, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 65 | Completed 27, Recruiting 19, Not yet recruiting 8, Terminated 7, Unknown 3, Withdrawn 1 |
| Phase 2 | 8 | Completed 4, Recruiting 2, Terminated 1, Withdrawn 1 |
Follow Tenecteplase: new trials by email Literature Review of Tenecteplase trials Research Report on Tenecteplase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tenecteplase Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 Hours Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg) - Acute Ischemic Stroke, Large Vessel Occlusion | Phase 3 | Not yet recruiting | Fujian Medical University Union Hospital | 1266 | 2027-04-01 | 2026-11-03 |
| INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 Mechanical Endovascular Thrombectomy, Intravenous Thrombolysis, Tenecteplase/Alteplase- depending upon availability at each treating centre - Stroke, Acute Ischemic, Medium Vessel Occlusion | Phase 3 | Not yet recruiting | University of Calgary | 800 | 2026-12-15 | 2026-10-30 |
| Intravenous Thrombolysis, Endovascular Treatment, or Bridging Therapy for Medium Vessel Occlusion Stroke Within 24 Hours Tenecteplase, Endovascular Treatment - Medium Vessel Occlusion Stroke (MeVO), Acute Ischemic Stroke | Phase 3 | Not yet recruiting | The First Affiliated Hospital of University of Science and Technology of China | 1395 | 2026-12-01 | 2026-11-12 |
| Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events rhTNK-tPA (0.25mg/kg), Reteplase 10 Units (U) plus a second dose of reteplase 10 U, No thrombolysis (thrombectomy alone) - Acute Ischemic Stroke, Large Vessel Occlusion | Phase 3 | Recruiting | Yongjun Wang | 1440 | 2026-10-16 | 2026-10-22 |
| Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg), Standard medical treatment - Acute Ischemic Stroke, Tenecteplase | Phase 3 | Recruiting | First Affiliated Hospital of Guangxi Medical University | 352 | 2026-09-24 | 2026-09-30 |
| Intra-arterial Thrombolysis For Acute Ischemic Stroke With Medium Vessel Occlusion Recombinant Tissue Plasminogen Activator (rt-PA), Intra-arterial Thrombolysis, Best Medical Management - Medium Vessel Occlusion, Ischemic Stroke, Acute | Phase 3 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 372 | 2026-09-19 | 2026-09-23 |
| ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 Tenecteplase or Alteplase- depending upon availability at each treating centre, Control - Stroke, Acute Ischemic, Endovascular Thrombectomy | Phase 3 | Recruiting | University of Calgary | 1500 | 2026-08-11 | 2026-10-21 |
| rhTNK-tPA for Acute Ischemic Stroke Under Simplified Imaging in the Extended Time Window Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg), Standard medical treatment - Acute Ischemic Stroke | Phase 3 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 750 | 2026-08-01 | 2026-06-15 |
| Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorrhage Neuronavigation-assisted Stereotactic Minimally Invasive Puncture Combined with Tenecteplase, Standard medical treatment - Intracerebral Hemorrhage Lobar | Phase 3 | Not yet recruiting | Beijing Tiantan Hospital | 636 | 2026-03-31 | 2026-03-25 |
| Reperfusion Completion Via Local Arterial Infusion of Tenecteplase After Incomplete Mechanical Thrombectomy Tenecteplase (0.0938mg/kg), Placebo - Stroke | Phase 3 | Not yet recruiting | Chuansheng Zhao | 344 | 2026-03-01 | 2026-03-13 |
| Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window Tenecteplase (0.25mg/kg), Standard Medical Management - Stroke | Phase 3 | Not yet recruiting | First Hospital of China Medical University | 864 | 2026-03-01 | 2026-03-17 |
| A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well Tenecteplase, Standard of care treatment - Acute Ischemic Stroke | Phase 3 | Recruiting | Boehringer Ingelheim | 1325 | 2026-02-17 | 2026-11-10 |
| Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg) - Acute Ischemic Stroke, Large Vessel Occlusion | Phase 3 | Recruiting | Xuanwu Hospital, Beijing | 572 | 2026-01-06 | 2026-08-19 |
| Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke Tenecteplase, Alteplase - Stroke, Ischemic, Stroke, Acute | Phase 3 | Recruiting | Xuanwu Hospital, Beijing | 850 | 2025-12-25 | 2026-04-09 |
| Tenecteplase vs Medical Management in 4.5-24h LVO no Access to EVT TNK, Standard medical treatment - Acute Ischemic Stroke, Large Vessel Occlusion | Phase 3 | Not yet recruiting | The First Affiliated Hospital of University of Science and Technology of China | 794 | 2025-11-01 | 2025-09-11 |
| Tenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST Trial Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg), Standard medical treatment - Stroke Ischemic | Phase 3 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 330 | 2025-09-01 | 2025-08-15 |
| Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg), Placebo - Acute Ischemic Stroke | Phase 3 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 912 | 2025-08-14 | 2025-12-16 |
| Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke Tenecteplase (0.25mg/kg), Standard medical treatment - Stroke, Ischemic, Medium Vessel Occlusions | Phase 3 | Recruiting | Beijing Tiantan Hospital | 596 | 2025-07-30 | 2026-04-01 |
| Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy (ALLY) II Trial tenecteplase - Ischemic Stroke, Acute Disease | Phase 2 / Phase 3 | Recruiting | ProMedica Health System | 132 | 2025-07-30 | 2026-01-21 |
| Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND Tenecteplase (0.25mg/kg), Standard medical treatment - Stroke | Phase 3 | Recruiting | Beijing Tiantan Hospital | 330 | 2025-05-30 | 2026-04-01 |
Showing 20 of 65. Sign in to see all of them.
Ischemic Stroke (39) · Stroke (19) · Myocardial Infarction (6) · ST Elevation Myocardial Infarction (3) · Cerebrovascular Disorders (2) · Hemorrhage (2) · Intracranial Thrombosis (2) · Pulmonary Embolism (2) · Retinal Artery Occlusion (2) · Acute Disease (1) · Brain Diseases (1) · Brain Infarction (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Cerebral Infarction (1)
Beijing Tiantan Hospital (8) · Boehringer Ingelheim (5) · Genentech, Inc. (5) · The First Affiliated Hospital of University of Science and Technology of China (5) · University of Calgary (5) · General Hospital of Shenyang Military Region (3) · Hospital Moinhos de Vento (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · University of Melbourne (2) · Xuanwu Hospital, Beijing (2) · AO GENERIUM (1) · Assistance Publique - Hôpitaux de Paris (1) · Chuansheng Zhao (1) · First Affiliated Hospital of Guangxi Medical University (1) · First Hospital of China Medical University (1)
China (29) · Canada (8) · Norway (8) · Australia (7) · Spain (6) · United States (6) · Austria (5) · Belgium (5) · Brazil (5) · Germany (5) · Finland (4) · France (4) · Sweden (4) · United Kingdom (4) · Denmark (3)
Bijoy K Menon, MD (3) · Raul G Nogueira, MD (3) · Barbara Gillespie, M.D., FASN (2) · Craig Anderson, MD (2) · Sheila CO Martins, MD, PhD (2) · Wei Hu, MD (2) · Yong Cao (2) · Andy Yong, MBBS (1) · Anthony Keech, MBBS (1) · Barbara Gillespie, MD, FASN (1) · Bijoy K Menon, MD, MSc (1) · Bruce Campbell (1) · Bruce Campbell, MD, PhD (1)
PMID 26387127, PMID 33857326, PMID 37830342, PMID 15262836, PMID 19092151, PMID 20133491, PMID 20598969, PMID 21111365, PMID 21315210, PMID 22172434, PMID 23473396, PMID 24716681, PMID 24916050, PMID 25161043, PMID 25433511, PMID 25691510, PMID 26304934, PMID 26783237, PMID 28335835, PMID 28525886, PMID 28780236, PMID 30602354, PMID 31009339, PMID 32511749, PMID 32631157, PMID 33446083, PMID 33464335, PMID 34564893, PMID 35262424, PMID 35369714, PMID 35525250, PMID 35590386, PMID 35779553, PMID 36549308, PMID 37247876, PMID 37800372, PMID 38124230, PMID 38174568, PMID 38275116, PMID 38329148, PMID 38676572, PMID 38768626, PMID 38884324, PMID 39264623, PMID 39379314, PMID 39424558, PMID 39435713, PMID 39567366, PMID 39654273, PMID 39689189
2018 (2), 2014 (1), 2023 (1), 2025 (1)